中医药成分防治肝缺血再灌注损伤的研究进展  

Research advances in the prevention and treatment of hepatic ischemia-reperfusion injury with traditional Chinese medicine components

作　　者：李振 曾意豪 王科 王凯强 俞科贤[2] LI Zhen;ZENG Yihao;WANG Ke;WANG Kaiqiang;YU Kexian(Graduate School,Qinghai University,Xining 810016,China;Medical College,Qinghai University,Xining 810016,China;First Department of Rehabilitation,Guangzhou Renai Tianhe Hospital,Guangzhou 510630,China)

机构地区：[1]青海大学研究生院,西宁810016 [2]青海大学医学院,西宁810016 [3]广州仁爱天河医院康复一科,广州510630

出　　处：《临床肝胆病杂志》2022年第2期471-476,共6页Journal of Clinical Hepatology

基　　金：国家中医药管理局——全国中医药创新骨干人才培训项目(国中医药人教函〔2019〕128号)。

摘　　要：肝缺血再灌注损伤(HIRI)是肝移植、肝脏切除及休克等疾病的一种极为常见的并发症。目前对于HIRI的研究较多,但临床仍缺乏根治性的药物。相关细胞、分子机制及通路、活性氧及氧化应激反应、一氧化氮及线粒体等多种因素介导了HIRI的发生和发展,这不仅导致患者生活质量降低,且危及患者生命安全。在HIRI发生机制的基础上结合相关文献,总结中医药成分防治HIRI的研究进展,旨在为HIRI的基础实验及临床研究提供理论支持。Hepatic ischemia-reperfusion injury(HIRI)is a very common complication of liver transplantation,liver resection,and shock.At present,many studies have been conducted on HIRI,but there is still a lack of drugs for radical treatment in clinical practice.Many factors,such as related cells,molecular mechanisms and signaling pathways,reactive oxygen species and oxidative stress response,nitric oxide,and mitochondria,mediate the development and progression of HIRI,which leads to the decline of patients’quality of life and even endangers their life safety.Based on the pathogenesis of HIRI and related articles,this article summarizes the research advances in the prevention and treatment of HIRI with traditional Chinese medicine components,so as to provide theoretical support for basic research and clinical research on HIRI.

关 键 词：肝疾病 再灌注损伤 中草药 治疗学 

分 类 号：R259[医药卫生—中西医结合]